Compare United States Brent Oil Fund LP (BNO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Zimmer Biomet Holdings Inc — how do they compare? United States Brent Oil Fund LP trades at $50.85, while Zimmer Biomet Holdings Inc trades at $95.94 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BNO | ZBH | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $107.71 |
52-Week Low | $27.20 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO is trading at $50.505, up 0.79% with a bullish technical outlook supported by moving averages. The oil market faces significant supply disruptions from Middle East tensions, particularly the Strait of Hormuz closure, creating volatility. Recent OPEC demand forecast cuts contrast with supply constraints, creating a complex fundamental backdrop for oil-related securities.
The stock presents opportunity from ongoing supply constraints but faces headwinds from demand destruction and inventory builds. Key risks include geopolitical resolution and demand volatility. Technical momentum remains positive near-term, but fundamental uncertainties require careful monitoring of oil market developments.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
